Revvity (RVTY) Morgan Stanley 24th Annual Global Healthcare Conference summary

Business transformation and strategic focus

• Shifted from a traditional instrument-based model to an innovation-driven life sciences and diagnostics company, emphasizing differentiation and recurring revenue streams.

• Portfolio simplification and cultural transformation have positioned the business in faster-growing, competitive markets.

• Financial performance has improved, with cash flow conversion consistently above 90% and operating margins rising from low 20s% to upper 20s%.

• Long-range organic growth target is 6%-8%, with diagnostics at the lower end and life sciences at the higher end.

Growth drivers and market positioning

• Diagnostics growth is led by reproductive health (notably newborn screening and Omics lab network) and immunodiagnostics, both outperforming long-term growth projections.

• Life sciences growth is driven by reagents (notably research reagents and flow cytometry) and software, with AI-related demand providing incremental tailwinds.

• Reagents business has outperformed peers due to strong customer service, rapid delivery, and a comprehensive value chain offering.

• Signals software business is positioned as an ERP for preclinical scientists, integrating AI tools and expected to double in size over four to five years.

AI integration and operational impact

• AI is driving tangible order growth, especially in preclinical research, with customers investing in infrastructure to maximize data output.

• The "lab in the loop" model is creating a validation bottleneck, as AI accelerates compound design but requires extensive wet lab validation.

• Signals' Xynthetica product links AI models directly to preclinical data, streamlining workflows and regulatory compliance.